LU92033I2 - Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) - Google Patents

Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)

Info

Publication number: LU92033I2
Authority: LU; Luxembourg
Prior art keywords: sub; atoms; nitrogen; formula; fused
Prior art date: 2001-07-31

Application number

LU92033C

Other languages

English (en)

Other versions

LU92033I9 (fr

Original Assignee

Genzyme Global S A R L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-31

Filing date

2012-06-27

Publication date

2012-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-27 Application filed by Genzyme Global S A R L filed Critical Genzyme Global S A R L

2012-08-27 Publication of LU92033I2 publication Critical patent/LU92033I2/fr

2019-01-03 Publication of LU92033I9 publication Critical patent/LU92033I9/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LU92033C 2001-07-31 2012-06-27 Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®) LU92033I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US30919601P	2001-07-31	2001-07-31
US38215502P	2002-05-20	2002-05-20
PCT/US2002/024212 WO2003011277A2 (fr)	2001-07-31	2002-07-30	Methodes de mobilisation de cellules souches/embryonnaires

Publications (2)

Publication Number	Publication Date
LU92033I2 true LU92033I2 (fr)	2012-08-27
LU92033I9 LU92033I9 (fr)	2019-01-03

Family

ID=26976666

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU92033C LU92033I2 (fr)	2001-07-31	2012-06-27	Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU00139C LUC00139I2 (fr)	2001-07-31	2019-11-26

Country Status (28)

Country	Link
US (9)	US6987102B2 (fr)
EP (3)	EP1411918B1 (fr)
JP (2)	JP5137288B2 (fr)
KR (2)	KR20040020075A (fr)
CN (2)	CN102302493B (fr)
AT (1)	ATE538785T1 (fr)
AU (1)	AU2002318927B2 (fr)
BE (1)	BE2019C544I2 (fr)
BR (1)	BRPI0211570B8 (fr)
CA (1)	CA2455559C (fr)
CY (4)	CY1112633T1 (fr)
DK (2)	DK1411918T3 (fr)
ES (2)	ES2380009T3 (fr)
FR (2)	FR12C0042I1 (fr)
HU (1)	HUP0402360A2 (fr)
IL (2)	IL159312A0 (fr)
LT (2)	LT2371361T (fr)
LU (2)	LU92033I2 (fr)
MX (1)	MXPA04000982A (fr)
NL (2)	NL300537I2 (fr)
NO (4)	NO336989B1 (fr)
NZ (1)	NZ530169A (fr)
PL (1)	PL364673A1 (fr)
PT (2)	PT1411918E (fr)
RU (1)	RU2309741C2 (fr)
SI (2)	SI2371361T1 (fr)
WO (1)	WO2003011277A2 (fr)
ZA (1)	ZA200400658B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7169750B2 (en) *	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
DK1411918T3 (da) *	2001-07-31	2012-04-23	Genzyme Global S A R L	Fremgangsmåder til at mobilisere progenitor/stamceller
PL369856A1 (en)	2001-12-21	2005-05-02	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) *	2001-12-21	2008-04-08	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005007838A1 (fr) *	2003-06-27	2005-01-27	Asahi Kasei Kabushiki Kaisha	Inhibiteur de differenciation cellulaire, procede de culture de cellules utilisant celui-ci, milieu de culture liquide et lignee de cellules cultivees
WO2005002522A2 (fr) *	2003-06-30	2005-01-13	Caritas St. Elizabeth's Medical Center Of Boston, Inc.	Compositions et methodes pour traiter une ischemie tissulaire
WO2005017160A2 (fr) *	2003-08-13	2005-02-24	Children's Hospital Medical Center	Mobilisation de cellules hematopoietques
WO2005017161A2 (fr)	2003-08-13	2005-02-24	Children's Hospital Medical Center	Peptides chimeriques pour regulation de gtpases
IL158868A0 (en) *	2003-11-13	2004-05-12	Yeda Res & Dev	Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (fr) *	2004-04-20	2005-11-03	Bayer Healthcare Ag	Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
JP2008509928A (ja) *	2004-08-13	2008-04-03	アノーメドインコーポレイテッド	前駆／幹細胞を動員するためのケモカインの組み合わせ
US8182806B2 (en) *	2004-09-07	2012-05-22	Johnson Lanny L	Synovial villi for use with tissue engineering
US7785582B2 (en) *	2004-09-07	2010-08-31	Johnson Lanny L	Use of synovium and omentum for tissue engineering
CA2586765A1 (fr) *	2004-11-05	2006-12-28	The General Hospital Corporation	Eloignement volontaire de cellules migratoires humaines d'une source d'agents
KR101604799B1 (ko)	2005-06-13	2016-03-28	클리브랜드 바이오랩스, 아이엔씨.	리포펩티드를 사용하여 아폽토시스에 대항하는 보호방법
US20070043012A1 (en) *	2005-08-19	2007-02-22	Bridger Gary J	Methods to enhance chemotherapy
EP1924606A4 (fr) *	2005-08-25	2010-01-13	Repair Technologies Inc	Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US8518349B2 (en)	2005-09-12	2013-08-27	Lanny Johnson	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) *	2005-09-12	2011-04-19	Johnson Lanny L	Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) *	2005-11-18	2007-05-24	Rensselaer Polytechnic Institute	Stem cells within gel microenvironments
CA2643209A1 (fr) *	2006-02-24	2007-09-20	Genzyme Corporation	Procedes servant a accroitre le debit sanguin et/ou a favoriser la regeneration d'un tissu
WO2007108689A2 (fr) *	2006-03-21	2007-09-27	Stichting Skeletal Tissue Engineering	Nouveau procede d'induction de la differenciation de cellules souches et progenitrices
CN101500595A (zh) *	2006-08-07	2009-08-05	健赞股份有限公司	组合治疗
US7883698B2 (en) *	2007-01-17	2011-02-08	Maria Michejda	Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (fr) *	2008-08-29	2010-03-04	Genzyme Corporation	Antagonistes du cxcr4 pour des lésions rénales
EP2493295A4 (fr)	2009-10-28	2013-05-08	Ford Henry Health System	Méthodes d'atténuation des lésions causées par une irradiation
CN101716167B (zh) *	2009-12-08	2011-12-28	中国人民解放军军事医学科学院野战输血研究所	一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
WO2012019168A2 (fr)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Acides nucléiques modifiés et leurs procédés d'utilisation
KR20140045411A (ko)	2011-05-16	2014-04-16	젠자임 코포레이션	Ｃｘｃｒ４ 길항제의 용도
US20160030522A1 (en) *	2013-03-15	2016-02-04	Leonard B. Miller	Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en)	2015-01-06	2018-06-05	Hamilton Sundstrand Corporation	Water injector for aviation cooling system
US11890348B2 (en)	2015-09-18	2024-02-06	The General Hospital Corporation	Localized delivery of anti-fugetactic agent for treatment of cancer
CA3008279A1 (fr)	2015-12-14	2017-06-22	X4 Pharmaceuticals, Inc.	Methodes de traitement du cancer
CN109069426B (zh)	2015-12-14	2021-10-29	X4 制药有限公司	治疗癌症的方法
WO2017106630A1 (fr)	2015-12-18	2017-06-22	The General Hospital Corporation	Polymères polyacétal, conjugués, particules et utilisations associées
WO2017112894A1 (fr)	2015-12-22	2017-06-29	X4 Pharmaceuticals, Inc.	Méthodes pour le traitement d'une maladie immunodéficiente
CA3019394A1 (fr)	2016-04-08	2017-10-12	X4 Pharmaceuticals, Inc.	Methodes de traitement du cancer
EP3471716A1 (fr) *	2016-06-16	2019-04-24	Centre National De La Recherche Scientifique	Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
ES2870920T3 (es)	2016-06-21	2021-10-28	X4 Pharmaceuticals Inc	Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh)	2016-06-21	2019-04-16	X4 制药有限公司	Cxcr4抑制剂及其用途
EP3472129A4 (fr)	2016-06-21	2019-12-04	X4 Pharmaceuticals, Inc.	Inhibiteurs de cxcr4 et leurs utilisations
WO2018049118A1 (fr)	2016-09-09	2018-03-15	The General Hospital Corporation	Protéine hsp hybride avec un agent anti-chimiorépulsif pour le traitement du cancer
US11453706B2 (en)	2016-09-09	2022-09-27	The General Hospital Corporation	HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018049120A1 (fr)	2016-09-09	2018-03-15	The General Hospital Corporation	Cellules présentatrices d'antigène ex vivo ou cellules t cd positives activées pour le traitement du cancer
WO2018106738A1 (fr)	2016-12-05	2018-06-14	Massachusetts Institute Of Technology	Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
US10058573B1 (en)	2017-12-06	2018-08-28	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem cells
CN111712262A (zh) *	2017-12-06	2020-09-25	美真达治疗公司	用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en)	2017-12-06	2022-03-01	Magenta Therapeutics, Inc.	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP3727371A4 (fr) *	2017-12-19	2021-10-27	GPCR Therapeutics, Inc.	Inhibiteurs d'hétéromères gpcr et leurs utilisations
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en)	2019-10-08	2024-08-13	The Regents Of The University Of California	Methods and compositions for hematopoietic stem cell mobilization
CA3171250A1 (fr)	2020-03-10	2021-09-16	E. Lynne KELLEY	Methodes de traitement de la neutropenie
EP4146797A1 (fr)	2020-05-06	2023-03-15	Orchard Therapeutics (Europe) Limited	Traitement pour les maladies neurodégénératives
WO2023056444A1 (fr)	2021-10-01	2023-04-06	Janssen Pharmaceutica N.V.	Procédés d'augmentation de la production de cellules progénitrices
WO2025224720A1 (fr)	2024-04-24	2025-10-30	Biolinerx Ltd.	Procédés de sélection de schéma thérapeutique contre des tumeurs solides
CN118987175A (zh) *	2024-08-13	2024-11-22	广东壹加再生医学研究院有限公司	普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US562476A (en) *		1896-06-23		Combined fence-wire reel and straightener
US4111199A (en) *	1977-03-31	1978-09-05	Isaac Djerassi	Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de)	1987-08-24	1989-03-16	Schering Ag	Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) *	1989-03-20	1990-09-21	Centre Nat Rech Scient	Procede de preparation de tetramines cycliques monofonctionnalisees
CA2069886A1 (fr)	1989-10-23	1991-04-24	David Love	Agents de chelation de metaux a sites multiples
US5021409A (en) *	1989-12-21	1991-06-04	Johnson Matthey Plc	Antiviral cyclic polyamines
US6001826A (en)	1989-12-21	1999-12-14	Anormed, Inc.	Chemical compounds
FR2672051B1 (fr) *	1991-01-24	1993-05-21	Guerbet Sa	Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en)	1991-03-15	1991-05-01	Johnson Matthey Plc	Improvements in chemical compounds
GB9126677D0 (en)	1991-12-16	1992-02-12	Johnson Matthey Plc	Improvements in chemical compounds
DE69309487T2 (de)	1992-11-13	1997-10-23	Univ Washington	Peripheralisierung hämatopoietischer stammzellen
GB9400411D0 (en)	1994-01-11	1994-03-09	Johnson Matthey Plc	Improvements in chemical compounds
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) *	1995-02-02	1995-03-22	Abuljadayel Ilham M S	A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en)	1995-03-30	1997-03-18	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) *	1995-05-02	1997-02-25	Johnson Matthey Plc	Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) *	1995-06-05	1997-02-25	Nippon Kayaku Co Ltd	末梢血液中の造血幹細胞数を増加するための薬剤
GB9511357D0 (en)	1995-06-06	1995-08-02	Johnson Matthey Plc	Improved antiviral compounds
US6506770B1 (en) *	1996-06-06	2003-01-14	Anormed, Inc.	Antiviral compounds
US5811544A (en) *	1995-08-28	1998-09-22	Johnson Matthey Plc	Process for preparing 1,4,8,11-tetraazacyclotetradecane
WO2000018885A1 (fr) *	1998-09-29	2000-04-06	Gamida Cell Ltd.	Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
CA2305787A1 (fr)	2000-05-09	2001-11-09	The University Of British Columbia	Traitement antagoniste cxcr4 de cellules hematopoietiques
ES2156581T5 (es) *	1998-03-30	2015-01-21	Northwest Biotherapeutics, Inc.	Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
WO1999065507A1 (fr) *	1998-06-19	1999-12-23	The General Hospital Corporation	Modulation de la fonction plaquettaire
CA2244554A1 (fr) *	1998-07-30	2000-01-30	Vasogen Inc.	Inhibition d'une greffe par rapport a la maladie d'un hote
JP2002529502A (ja) *	1998-11-17	2002-09-10	スミスクライン・ビーチャム・コーポレイション	血小板減少症の治療法
EP1016413A1 (fr) *	1998-12-30	2000-07-05	Applied Research Systems ARS Holding N.V.	Hormone de croissance humaine (HGH) pour stimuler la mobilisation de cellules souches hematopoietiques pluripotentes
US6365583B1 (en) *	1999-02-02	2002-04-02	Anormed, Inc.	Methods to enhance white blood cell count
AP1654A (en)	1999-03-24	2006-09-01	Anormed Inc	Chemokine receptor binding heterocyclic compounds.
WO2000066112A1 (fr) *	1999-05-03	2000-11-09	Smithkline Beecham Corporation	Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
AU2334301A (en) *	1999-12-17	2001-06-25	Anormed Inc.	Chemokine receptor binding heterocyclic compounds
EP1286684B1 (fr)	2000-05-09	2004-04-28	The University Of British Columbia	Utilisation d'antagonistes du cxcr4 pour traiter les maladies autoimmunes et le cancer
MXPA02012067A (es) *	2000-06-05	2004-08-19	Univ Columbia	Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
US6734191B2 (en)	2000-09-15	2004-05-11	Anormed, Inc.	Chemokine receptor binding heterocyclic compounds
DE60137435D1 (de)	2000-09-15	2009-03-05	Anormed Inc	Chemokin rezeptor bindenden heterozyklische verbindungen
HK1052011A1 (zh)	2000-09-15	2003-08-29	Anormed Inc.	趋化因子受体结合杂环化合物
DE60136476D1 (de)	2000-09-29	2008-12-18	Anormed Inc	-stickstoffhaltigen zyklischen polyaminen und deren verbindungen
CA2431611A1 (fr)	2001-01-23	2002-08-01	P&G-Clairol, Inc.	Intermediaires primaires pour coloration capillaire oxydante
US7169750B2 (en)	2001-07-31	2007-01-30	Anormed, Inc.	Methods to mobilize progenitor/stem cells
DK1411918T3 (da)	2001-07-31	2012-04-23	Genzyme Global S A R L	Fremgangsmåder til at mobilisere progenitor/stamceller
PL369856A1 (en)	2001-12-21	2005-05-02	Anormed Inc.	Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE102014206089B4 (de)	2014-03-31	2018-01-18	BSH Hausgeräte GmbH	Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

2002
- 2002-07-30 DK DK02750370.5T patent/DK1411918T3/da active
- 2002-07-30 NZ NZ530169A patent/NZ530169A/en not_active IP Right Cessation
- 2002-07-30 KR KR10-2004-7001333A patent/KR20040020075A/ko not_active Ceased
- 2002-07-30 DK DK10184509.7T patent/DK2371361T3/da active
- 2002-07-30 CN CN201010282230.3A patent/CN102302493B/zh not_active Expired - Lifetime
- 2002-07-30 IL IL15931202A patent/IL159312A0/xx unknown
- 2002-07-30 EP EP02750370A patent/EP1411918B1/fr not_active Revoked
- 2002-07-30 WO PCT/US2002/024212 patent/WO2003011277A2/fr not_active Ceased
- 2002-07-30 PT PT02750370T patent/PT1411918E/pt unknown
- 2002-07-30 HU HU0402360A patent/HUP0402360A2/hu unknown
- 2002-07-30 JP JP2003516507A patent/JP5137288B2/ja not_active Expired - Lifetime
- 2002-07-30 PT PT10184509T patent/PT2371361T/pt unknown
- 2002-07-30 KR KR1020097024731A patent/KR100996378B1/ko not_active Expired - Lifetime
- 2002-07-30 EP EP10184509.7A patent/EP2371361B1/fr not_active Revoked
- 2002-07-30 SI SI200231096T patent/SI2371361T1/sl unknown
- 2002-07-30 ES ES02750370T patent/ES2380009T3/es not_active Expired - Lifetime
- 2002-07-30 MX MXPA04000982A patent/MXPA04000982A/es active IP Right Grant
- 2002-07-30 AU AU2002318927A patent/AU2002318927B2/en not_active Expired
- 2002-07-30 US US10/209,001 patent/US6987102B2/en not_active Expired - Lifetime
- 2002-07-30 ES ES10184509T patent/ES2742730T3/es not_active Expired - Lifetime
- 2002-07-30 SI SI200230976T patent/SI1411918T1/sl unknown
- 2002-07-30 CA CA2455559A patent/CA2455559C/fr not_active Expired - Lifetime
- 2002-07-30 EP EP19179517.8A patent/EP3632425A1/fr not_active Withdrawn
- 2002-07-30 LT LTEP10184509.7T patent/LT2371361T/lt unknown
- 2002-07-30 AT AT02750370T patent/ATE538785T1/de active
- 2002-07-30 BR BR0211570-0 patent/BRPI0211570B8/pt not_active IP Right Cessation
- 2002-07-30 PL PL02364673A patent/PL364673A1/xx unknown
- 2002-07-30 RU RU2004105961/15A patent/RU2309741C2/ru active Protection Beyond IP Right Term
- 2002-07-30 CN CN028149955A patent/CN1561208B/zh not_active Expired - Lifetime
2003
- 2003-12-11 IL IL159312A patent/IL159312A/en active IP Right Grant
2004
- 2004-01-27 ZA ZA2004/00658A patent/ZA200400658B/en unknown
- 2004-01-29 NO NO20040407A patent/NO336989B1/no active Protection Beyond IP Right Term
2005
- 2005-11-08 US US11/269,773 patent/US7935692B2/en not_active Expired - Lifetime
2006
- 2006-06-02 US US11/446,390 patent/US20060223180A1/en not_active Abandoned
2007
- 2007-08-20 US US11/841,837 patent/US7897590B2/en not_active Expired - Lifetime
2008
- 2008-04-11 JP JP2008104148A patent/JP2008195730A/ja not_active Withdrawn
2011
- 2011-02-08 US US13/023,381 patent/US20110129448A1/en not_active Abandoned
2012
- 2012-03-07 CY CY20121100223T patent/CY1112633T1/el unknown
- 2012-06-27 LU LU92033C patent/LU92033I2/fr unknown
- 2012-06-27 CY CY2012017C patent/CY2012017I1/el unknown
- 2012-06-28 NL NL300537C patent/NL300537I2/nl unknown
- 2012-06-28 FR FR12C0042C patent/FR12C0042I1/fr active Active
2013
- 2013-03-14 US US13/826,913 patent/US20130273009A1/en not_active Abandoned
2014
- 2014-10-03 US US14/506,297 patent/US20150246019A1/en not_active Abandoned
2015
- 2015-05-27 NO NO20150674A patent/NO344632B1/no not_active IP Right Cessation
2016
- 2016-03-18 US US15/074,836 patent/US20170049747A1/en not_active Abandoned
- 2016-06-10 NO NO2016011C patent/NO2016011I1/no unknown
2018
- 2018-08-21 US US16/107,761 patent/US20190216773A1/en not_active Abandoned
2019
- 2019-08-20 CY CY20191100889T patent/CY1122199T1/el unknown
- 2019-10-10 FR FR19C1058C patent/FR19C1058I2/fr active Active
- 2019-10-14 CY CY2019038C patent/CY2019038I2/el unknown
- 2019-10-23 BE BE2019C544C patent/BE2019C544I2/fr unknown
- 2019-11-19 LT LTPA2019018C patent/LTC2371361I2/lt unknown
- 2019-11-26 LU LU00139C patent/LUC00139I2/fr unknown
2020
- 2020-01-22 NL NL301031C patent/NL301031I2/nl unknown
- 2020-03-05 NO NO2020003C patent/NO2020003I1/no unknown

Also Published As

Publication number	Publication date
FR12C0042I1 (fr)	2012-08-10
PL364673A1 (en)	2004-12-13
US20060223180A1 (en)	2006-10-05
CN102302493B (zh)	2015-08-12
NL301031I1 (nl)	2020-02-05
SI2371361T1 (sl)	2019-10-30
KR20040020075A (ko)	2004-03-06
CY1122199T1 (el)	2020-05-29
LU92033I9 (fr)	2019-01-03
BE2019C544I2 (fr)	2021-07-19
JP5137288B2 (ja)	2013-02-06
KR100996378B1 (ko)	2010-11-25
HK1063005A1 (en)	2004-12-10
HUP0402360A2 (hu)	2005-02-28
ES2380009T3 (es)	2012-05-07
WO2003011277A3 (fr)	2003-05-22
EP3632425A1 (fr)	2020-04-08
NZ530169A (en)	2007-04-27
EP1411918A2 (fr)	2004-04-28
US20080063624A1 (en)	2008-03-13
CN102302493A (zh)	2012-01-04
NO20150674A1 (no)	2015-05-27
US20190216773A1 (en)	2019-07-18
US20110129448A1 (en)	2011-06-02
JP2004538303A (ja)	2004-12-24
BRPI0211570B1 (pt)	2020-01-28
FR19C1058I1 (fr)	2019-11-22
NO20040407L (no)	2004-03-19
IL159312A0 (en)	2004-06-01
NL300537I2 (fr)	2017-02-02
US7935692B2 (en)	2011-05-03
BR0211570A (pt)	2004-07-13
DK2371361T3 (da)	2019-08-19
CY2019038I1 (el)	2020-05-29
CY2019038I2 (el)	2020-05-29
ES2742730T3 (es)	2020-02-17
LTPA2019018I1 (lt)	2019-12-10
EP1411918A4 (fr)	2007-11-14
PT2371361T (pt)	2019-09-10
LUC00139I2 (fr)	2021-02-10
JP2008195730A (ja)	2008-08-28
ZA200400658B (en)	2005-07-27
MXPA04000982A (es)	2004-04-20
CY2012017I2 (el)	2015-08-05
CA2455559C (fr)	2012-01-10
BRPI0211570B8 (pt)	2021-05-25
ATE538785T1 (de)	2012-01-15
CY1112633T1 (el)	2015-08-05
NO344632B1 (no)	2020-02-17
EP2371361B1 (fr)	2019-08-07
NO2020003I1 (no)	2020-03-05
EP2371361A1 (fr)	2011-10-05
LUC00139I1 (fr)	2019-11-27
IL159312A (en)	2015-05-31
US6987102B2 (en)	2006-01-17
US20170049747A1 (en)	2017-02-23
US20030130250A1 (en)	2003-07-10
NO336989B1 (no)	2015-12-14
AU2002318927B2 (en)	2007-01-04
LTC2371361I2 (lt)	2021-09-27
CN1561208A (zh)	2005-01-05
FR19C1058I2 (fr)	2020-10-23
RU2309741C2 (ru)	2007-11-10
US20130273009A1 (en)	2013-10-17
PT1411918E (pt)	2012-03-06
KR20090130152A (ko)	2009-12-17
SI1411918T1 (sl)	2012-04-30
NL301031I2 (nl)	2020-07-20
LT2371361T (lt)	2019-09-10
US20060193826A1 (en)	2006-08-31
EP1411918B1 (fr)	2011-12-28
US7897590B2 (en)	2011-03-01
CA2455559A1 (fr)	2003-02-13
WO2003011277A2 (fr)	2003-02-13
RU2004105961A (ru)	2005-03-20
CN1561208B (zh)	2010-11-10
CY2012017I1 (el)	2015-08-05
US20150246019A1 (en)	2015-09-03
DK1411918T3 (da)	2012-04-23
NO2016011I1 (no)	2016-06-10

Publication	Publication Date	Title
LTC2371361I2 (lt)	2021-09-27	Pirmtakų/kamieninių ląstelių suaktyvinimo būdai
AP1497A (en)	2005-11-20	Methods and compositions to enhance white blood cell count.
MXPA05003193A (es)	2005-06-08	Compuesto de adenina novedoso y uso del mismo.
EA200200708A1 (ru)	2003-02-27	Производные бензазола и их применение в качестве модуляторов jnk
KR880005093A (ko)	1988-06-28	5-알킬벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 약제학적 조성물
KR920012082A (ko)	1992-07-25	Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
EA200501148A1 (ru)	2006-04-28	Пиридилоксиметильные и бензизоксазольные азабициклические производные
ES8800936A1 (es)	1987-12-01	Un procedimiento para la obtencion de derivados de bi- y triciclicos de piridona
ES2262504T3 (es)	2006-12-01	Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.
WO1999023092A3 (fr)	1999-08-05	3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
OA09239A (fr)	1992-06-30	"Nouveaux céphèmes et procédés pour leur préparation".
EA200101050A1 (ru)	2002-04-25	Замещенные бензолактамные соединения
EA200000527A2 (ru)	2000-12-25	Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
DE69904025D1 (de)	2003-01-02	Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
WO2007106063A3 (fr)	2007-12-21	Procédés servant à accroître le débit sanguin et/ou à favoriser la régénération d'un tissu
EA200001157A2 (ru)	2001-06-25	Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
FR2823749B1 (fr)	2004-02-20	Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant